



**Holista CollTech Limited**

(ASX:HCT / ABN 24 094 515 992)

283 Rokeby Road Subiaco WA 6008

P: +61 8 6141 3500 ; F: +61 8 6141 3599 W: [www.holistaco.com](http://www.holistaco.com)

## ASX Announcement

**31 October 2019**

### **HOLISTA COLLTECH LIMITED APPENDIX 4C QUARTERLY REPORT**

Holista CollTech Limited (**Holista**, or **the Company**) (ASX CODE: HCT) is pleased to release the Appendix 4C for the quarter ending 30 September 2019.

Holista subsidiary companies collectively continue their strong sales in local health products, and growing demand for high margin collagen products. This result has reduced demand from subsidiary companies for financial support. The food ingredients and collagen enjoy an increasing sales profile with no additional costs other than direct inputs with better margins. This has led to the following:

- The Company expect total sales collection of A\$1,514,000 in the next quarter.
- Of this, A\$330,000 will be in by the week ending 8<sup>th</sup> November 2019.
- In addition to this, we are also in the process of negotiation of payment of A\$87,600 from the MLM company called iGalen that we supply to and that payment is expected by the middle of November 2019.
- We also expect more payment from iGalen in December 2019.
- Holista has shipped a maiden order of GI Lite™ worth of A\$74,500 to Kawan Food, and is expected to increase. The full payment for that will also be coming at in this quarter.
- Holista will ship its first Low-GI sugar, 80Less™ to customer worth A\$20,000 in the next quarter.
- Corporate overheads have been successfully lowered as a proportion of sales and continue to decline.
- The Company has also been able to negotiate more favorable terms from our suppliers.
- Subsequent to the delivery of its first container of low Glycemic index noodles from US subsidiary to various Chinese parties, the Company will deliver another container of noodles to Korea in the next quarter.
- Holista anticipates shipping A\$218,700 of cosmetic ovine collagen in this quarter against confirmed orders.

The Company confirms it is in compliance with Listing Rule 3.1 and that it is not aware of any other information that has not already been released to the market.

**ENDS**

**For further information, please contact:**

**Corporate Affairs & Business Opportunities**

Dr Rajen Manicka: rajen.m@holistaco.com

General Enquiries: enquiries@holistaco.com

**Australia**

283 Rokeby Road

Subiaco WA 6008

**P: +61 8 6141 3500 ; F: +61 8 6141 3599**

**Malaysia**

12th Floor, Amcorp Trade Centre, PJ Tower

No. 18, Persiaran Barat off Jalan Timur

46000, Petaling Jaya, Malaysia

**P: +603 7965 2828 ; F: +603 7965 2777**

**Media and Investor Relations Enquiries**

WeR1 Consultants Pte Ltd

3 Phillip Street #12-01

Singapore 048693

holista@wer1.net; **P: +65 67374844**

**About Holista CollTech Ltd**

Holista CollTech Ltd (**Holista**) is a research-driven biotech company and is the result of the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth with extensive operations in Malaysia, Holista is dedicated to delivering first-class natural ingredients and wellness products and leads in research on herbs and food ingredients.

Holista, listed on the Australia Securities Exchange, researches, develops, manufactures and markets “health-style” products to address the unmet and growing needs of natural medicine. Holista’s suite of ingredients is capable of serving the industry to provide low-GI baked products, low sodium salt, low fat fried foods and low calories sugar without compromise in taste, odour and mouth feel. It is the only company to produce sheep (ovine) collagen using patented extraction methods.

# Appendix 4C

## Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

**HOLISTA COLLTECH LIMITED (ASX:HCT)**

ABN

**24 094 515 992**

Quarter ended (Current quarter)

**30 September 2019**

### Consolidated statement of cash flows

	Current quarter \$A'000	Year to date (9 Months) \$A'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	1,430	5,130
1.2 Payments for:		
(a) research and development	(35)	(92)
(b) product manufacturing and operating costs	(684)	(2,572)
(c) advertising and marketing	(101)	(251)
(d) leased assets	-	-
(e) staff costs	(742)	(2,132)
(f) administration and corporate costs	(96)	(357)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(25)	(59)
1.6 Income taxes (paid) / refunded	(9)	(22)
1.7 Government grants and tax incentives	-	134
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(262)</b>	<b>(221)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	(4)	(72)
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	(5)	(22)
(e) other non-current assets	45	42
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	(22)	51
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material):	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>14</b>	<b>( 1)</b>

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 Months) \$A'000
<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	(11)	(68)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>(11)</b>	<b>(68)</b>
<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	331	358
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(262)	(221)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	14	( 1)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(11)	(68)
4.5 Effect of movement in exchange rates on cash held	9	13
<b>4.6 Cash and cash equivalents at end of quarter</b>	<b>81</b>	<b>81</b>
<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1 Bank balances	81	331
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
<b>5.5 Cash and cash equivalents at end of quarter</b> (should equal item 4.6 above)	<b>81</b>	<b>331</b>
<b>6. Payments to directors of the entity and their associates</b>		<b>Current quarter \$A'000</b>
6.1 Aggregate amount of payments to these parties included in item 1.2		89
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3 and 2.5		-
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	In respect to 6.1: Salaries and consulting fees paid to directors and their related parties.	
<b>7. Payments to related entities of the entity and their associates</b>		<b>Current quarter \$A'000</b>
7.1 Aggregate amount of payments to these parties included in item 1.2		-
7.2 Aggregate amount of cash flow from loans to these parties included in items 2.3		-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	Nil	

<b>8. Financing facilities available</b> Add notes as necessary for an understanding of the position	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
8.1 Loan facilities	492	492
8.2 Credit standby arrangements	283	247
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Loan facilities: This is secured term loan with RHB bank in Malaysia, interest rates ranging from 4.76% to 6.73%.  
Credit standby arrangements: This is banker acceptance bears interest of 5.55% with CIMB bank in Malaysia. This is secured loan by pledging fixed deposits.

<b>9. Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1 Research and development	30
9.2 Product manufacturing and operating costs	580
9.3 Advertising and marketing	90
9.4 Leased assets	-
9.5 Staff costs	700
9.6 Administration and corporate costs	90
9.7 Other (provide details if material):	-
<b>9.8 Total estimated cash outflows</b>	<b>1,490</b>

<b>10. Acquisitions and disposals of business entities</b> (items 2.1(b) and 2.2(b) above)	<b>Acquisitions</b>	<b>Disposals</b>
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal (\$A'000)	-	-
10.4 Total net assets / (deficiency) (\$A'000)	-	-
10.5 Nature of business	-	-

## Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Signed: \_\_\_\_\_ Dated: Thursday, 31 October 2019

Company Secretary

Print name: BRETT FRASER

## Notes

- The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.